The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma
Open accessAbstract
Dendritic cells (DCs) are considered to be promising adjuvants for inducing immunity to cancer. We used mature, monocyte-derived DCs to elicit resistance to malignant melanoma. The DCs were pulsed with Mage-3A1 tumor peptide and a recall antigen, tetanus toxoid or tuberculin. 11 far advanced stage IV melanoma patients, who were progressive despite standard chemotherapy, received five DC vaccinations at 14-d intervals. The first three vaccinations were administered into the skin, 3 × 106 DCs each subcutaneously and intradermally, followed by two intravenous injections of 6 × 106 and 12 × 106 DCs, respectively. Only minor (less than or equal to grade II) side effects were observed. Immunity to the recall antigen was boosted. Significant expansions of Mage-3A1–specific CD8+ cytotoxic T lymphocyte (CTL) precursors were induced in 8/11 patients. Curiously, these immune responses often declined after the intravenous vaccinations. Regressions of individual metastases (skin, lymph node, lung, and liver) were evident in 6/11 patients. Resolution of skin metastases in two of the patients was accompanied by erythema and CD8+ T cell infiltration, whereas nonregressing lesions lacked CD8+ T cells as well as Mage-3 mRNA expression. This study proves the principle that DC “vaccines” can frequently expand tumor-specific CTLs and elicit regressions even in advanced cancer and, in addition, provides evidence for an active CD8+ CTL–tumor cell interaction in situ as well as escape by lack of tumor antigen expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Self-citationVaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862 · cited 5×
“(11) to detect Mage-3A1 immunity (not shown).”
BackgroundMethodResultInfluentialVaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804
Dieu, M.-C., Vanbervliet, B., Vicari, A., Bridon, J.-M., Oldham, E., Aït-Yahia, S., Brière, F., Zlotnik, A., Lebecque, S., & Caux, C. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.373 · Cited by 1,425
Activation of human dendritic cells through CD40 cross-linking.
Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., Van Kooten, C., Durand, I., & Banchereau, J. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1263 · Cited by 1,317
Jonuleit, H., Kühn, U., Müller, G., Steinbrink, K., Paragnik, L., Schmitt, E., Knop, J., & Enk, A. H. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271209 · Cited by 1,163
Self-citationInflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells
Cella, M., Engering, A., Pinet, V., Pieters, J., & Lanzavecchia, A. (1997) · Nature · doi:10.1038/42030 · Cited by 1,123
Romani, N., Reider, D., Heuer, M., Ebner, S., Kämpgen, E., Eibl, B., Niederwieser, D., & Schuler, G. (1996) · Journal of Immunological Methods · doi:10.1016/0022-1759(96)00078-6 · Cited by 1,091
Self-citationAnderson, P. C. (1999) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.281.24.2351 · Cited by 1,006
Simulated response of the ocean carbon cycle to anthropogenic climate warming
Sarmiento, J. L., Hughes, T. M. C., Stouffer, R. J., & Manabe, S. (1998) · Nature · doi:10.1038/30455 · Cited by 899
Wong, B. R., Josien, R., Lee, S. Y., Sauter, B., Li, H.-L., Steinman, R. M., & Choi, Y. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.12.2075 · Cited by 853
Self-citationMarchand, M., van Baren, N., Weynants, P., Brichard, V., Dr�no, B., Tessier, M.-H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., et al. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s · Cited by 784
Gaugler, B., Van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethé, B., Brasseur, F., & Boon, T. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.921 · Cited by 762
Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily.
Zhou, L. J., & Tedder, T. F. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.8.3821 · Cited by 736
Van den Eynde, B. J., & van der Bruggen, P. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80050-7 · Cited by 623
Romero, P., Rod Dunbar, P., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J.-L., Liénard, D., Cerottini, J.-C., & Cerundolo, V. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1641 · Cited by 521
Steinbrink, K., Jonuleit, H., Müller, G., Schuler, G., Knop, J., & Enk, A. H. (1999) · Blood · doi:10.1182/blood.v93.5.1634 · Cited by 511
Self-citationThurner, B., Röder, C., Dieckmann, D., Heuer, M., Kruse, M., Glaser, A., Keikavoussi, P., Kämpgen, E., Bender, A., & Schuler, G. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00208-7 · Cited by 482
Self-citationDhodapkar, M. V., Steinman, R. M., Sapp, M., Desai, H., Fossella, C., Krasovsky, J., Donahoe, S. M., Dunbar, P. R., Cerundolo, V., Nixon, D. F., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6909 · Cited by 468
Self-citationPardoll, D. M. (1998) · Nature Medicine · doi:10.1038/nm0598supp-525 · Cited by 428
Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors
Schuler, G., & Steinman, R. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1183 · Cited by 416
Self-citationMurphy, G., Tjoa, B., Ragde, H., Kenny, G., & Boynton, A. (1996) · The Prostate · doi:10.1002/(sici)1097-0045(199612)29:6<371::aid-pros5>3.0.co;2-b · Cited by 400
Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
Enk, A. H., Jonuleit, H., Saloga, J., & Knop, J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971104)73:3<309::aid-ijc1>3.0.co;2-3 · Cited by 386
Self-citationLanzavecchia, A. (1998) · Nature · doi:10.1038/30845 · Cited by 360
Generation of Mature Dendritic Cells from Human Blood
Schuler, G., & Romani, N. (1997) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4757-9966-8_2 · Cited by 309
Self-citationMelanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.
Topalian, S. L., Gonzales, M. I., Parkhurst, M., Li, Y. F., Southwood, S., Sette, A., Rosenberg, S. A., & Robbins, P. F. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.5.1965 · Cited by 257
Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes
Chaux, P., Vantomme, V., Stroobant, V., Thielemans, K., Corthals, J., Luiten, R., Eggermont, A. M. M., Boon, T., & van der Bruggen, P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.5.767 · Cited by 234
Shimizu, K., Fields, R. C., Giedlin, M., & Mulé, J. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2268 · Cited by 172
Herr, W., Linn, B., Leister, N., Wandel, E., Büschenfelde, K. M. Z., & Wölfel, T. (1997) · Journal of Immunological Methods · doi:10.1016/s0022-1759(97)00019-7 · Cited by 139
Dendritic Cells: Biology and Clinical Applications
Ploegh, H. L. (1999) · Nature Medicine · doi:10.1038/12406 · Cited by 138
Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma
Dummer, W., Becker, J. C., Schwaaf, A., Leverkus, M., Moll, T., & Br�cker, E.-B. (1995) · Melanoma Research · doi:10.1097/00008390-199502000-00008 · Cited by 132
Self-citationInterleukin 10 production by human melanoma.
Sato, T., McCue, P. A., Masuoka, K., Salwen, S. A., Lattime, E. C., Mastrangelo, M. J., & Berd, D. (1996) · PubMed · Cited by 112
Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy
Romero, P. J., Cerottini, J., & Waanders, G. A. (1998) · Molecular Medicine Today · doi:10.1016/s1357-4310(98)01280-5 · Cited by 84
New opportunities for the development of cancer immunotherapies.
Rosenberg, S. A. (1998) · PubMed · Cited by 16
Cited by
Steinman, R. M., Hawiger, D., & Nussenzweig, M. C. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141040 · Cited by 3,122
Self-citationCancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Antigen Presentation and T Cell Stimulation by Dendritic Cells
Guermonprez, P., Valladeau, J., Zitvogel, L., Théry, C., & Amigorena, S. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064828 · Cited by 1,926
Metadata
- Authors
- Thurner, B., Haendle, I., Röder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch, P., Bröcker, E. B., Steinman, R. M., Enk, A., Kämpgen, E., & Schuler, G.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1999-12-06
- Volume
- 190
- Issue
- 11
- Pages
- 1669-1678
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2117216774
- Cited by
- 1,226
- References
- 34
- FWCI
- 33.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.